Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 10Neoplasms 9Leukemia 5Myelodysplastic Syndromes 3Carcinoma 3Hematologic Diseases 2Small Cell Lung Carcinoma 1Sarcoma, Myeloid 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1Acute Disease 1

Interventions

Cisplatin 7Etoposide 5pembrolizumab 4Topotecan 4Pemetrexed 4Gemcitabine 3Carboplatin 3belinostat 2Temozolomide 2RRx-001 2Paclitaxel 2vosaroxin 1vinflunine 1veliparib 1taxane 1sagopilone 1sacituzumab govitecan 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1bemiparin 1belotecan 1apalutamide 1alvocidib 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Small Cell × vosaroxin × Clear all
NCT00298896 2018-07-26

Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

Sunesis Pharmaceuticals

Phase 2 Completed
55 enrolled 10 charts
Thoracic

Carcinoma, Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡